Timothy Oldham

Dr Oldham has more than 15 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a particular focus on biologics, cell and gene therapies and pharmaceutical product.. His expertise spans life sciences strategy and business development, commercial and manufacturing operations and alliance management across Europe, Asia and Australia, with a focus on biologic and cellular therapies and pharmaceuticals. Immediately prior to AdAlta, Dr Oldham was Executive Leader at Tijan Ventures, providing strategic planning, capital raising, interim executive management and board leadership to transform and grow life sciences companies with a focus in the fields of immunotherapy and cell and gene therapy. Previous roles have included CEO and Managing Director of Cell Therapies Pty Ltd, and a variety of senior management roles with Mayne Pharma Ltd in Europe prior to its acquisition by Hospira. Dr Oldham is currently Non-Executive Director of transdermal drug delivery company, Acrux Ltd (ASX: ACR) and bispecific antibody company, Immunexus Ltd. He is also a member of the Board of BioMelbourne Network Inc.